Citadel Advisors’s ASP Isotopes ASPI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.22M Sell
357,591
-410,415
-53% -$2.42M ﹤0.01% 6317
2026
Q1
$3.39M Sell
768,006
-957,547
-55% -$5.66M ﹤0.01% 5017
2025
Q4
$9.23M Buy
1,725,553
+559,788
+48% +$4.45M ﹤0.01% 3364
2025
Q3
$11.2M Buy
1,165,765
+1,020,562
+703% +$9.41M ﹤0.01% 3103
2025
Q2
$1.07M Buy
+145,203
New +$974K ﹤0.01% 6941
2024
Q2
Sell
-50,695
Closed -$209K 14208
2024
Q1
$209K Sell
50,695
-53,844
-52% -$166K ﹤0.01% 10224
2023
Q4
$187K Buy
+104,539
New +$153K ﹤0.01% 10049

Other funds holding ASPI

Citadel Advisors's ASPI Position: Q2 2026 in Review

Citadel Advisors reduced its ASP Isotopes (ASPI) stake by 53% in Q2 2026, selling an estimated $2.42M and leaving 357,591 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #6317.

Citadel Advisors first reported a position in ASPI in Q4 2023 and has held it in 7 quarters since. The position peaked at $11.2M in Q3 2025. 185 funds tracked by Wall St. Rank hold ASPI as of Q2 2026.

  • Citadel Advisors held 357,591 shares of ASP Isotopes worth $2.22M as of Q2 2026.
  • Citadel Advisors sold 410,415 ASP Isotopes shares in Q2 2026, an estimated $2.42M.
  • ASP Isotopes made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6317 holding.
  • Citadel Advisors first reported a position in ASP Isotopes in Q4 2023 and has held it in 7 quarters since.
  • Citadel Advisors's ASP Isotopes position peaked at $11.2M in Q3 2025.
  • 185 funds tracked by Wall St. Rank held ASP Isotopes as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.